西妥昔单抗引起味觉、嗅觉丧失1例  

One case of ageustia and anosphrasia induced by cetuximab injection

作　　者：李馨艳[1] 费小非[1] 杨梅[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院药剂科,北京100021

出　　处：《中国新药杂志》2013年第7期857-858,共2页Chinese Journal of New Drugs

摘　　要：西妥昔单抗是一种嵌合型单克隆抗体,能特异性与表皮生长因子受体(epidermal growth factorreceptor,EGFR)结合,抑制肿瘤细胞的增殖。本文报道1例男性患者使用西妥昔单抗注射液联合放射治疗扁桃体鳞癌,首次给予西妥昔单抗负荷剂量400 mg.m-2,3 d后患者出现味觉、嗅觉丧失。以后每周给予维持剂量250 mg.m-2,6周,放疗28次,患者病情好转出院。6个月后患者复诊,自诉味觉、嗅觉丧失仍存在。Cetuximab is a chimeric monoclonal antibody specifically binding the epidermal growth factor re- ceptor （EGFR） and inhibiting the growth of the tumor cells. This article reports a male patient who was applied with cetuximab injection combined with radiotherapy of the tonsil squamous cell carcinoma. The patient experienced ageustia and anosphrasia three days after using a loading dose of 400 mg·m-2 cetuximab for the first time. With the maintenance dose of 250 mg·m-2 each week during the coming six weeks and radiotherapy for twenty-eight times, the patient＇s conditions were improved and left the hospital. Six months later the patient was reviewed and still re- ported his ageustia and anosphrasia.

关 键 词：西妥昔单抗 扁桃体癌 味觉丧失 嗅觉丧失 药物不良反应 

分 类 号：R979.1[医药卫生—药品]